219672-23-8

Basic information

• Product Name: Benzoic acid, 4-(1-oxido-4-pyridinyl)-
• Synonyms: 4-(1-oxido-4-pyridinyl)-Benzoic acid
• CAS NO: 219672-23-8
• Molecular Formula: C₁₂H₉NO₃
• Molecular Weight: 215.2
• Mol File: 219672-23-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(1-oxido-4-pyridinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(1-oxido-4-pyridinyl)-(219672-23-8)
• EPA Substance Registry System: Benzoic acid, 4-(1-oxido-4-pyridinyl)-(219672-23-8)

Safety Data

• Hazardous Substances Data: 219672-23-8(Hazardous Substances Data)

Downstream Products

• 370863-46-0 3-{1-[4-(1-Oxypyridin-4-yl)-benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}benzamidine trifluoroacetate 
• 1352902-97-6 [Co(4-(4-pyridyl)benzoate N-oxide)(azide)(H₂O)]n 
• 1352902-99-8 [Ni(4-(4-pyridyl)benzoate N-oxide)(azide)(H₂O)]n 

Relevant articles and documents

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.